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Abstract
Background: Cardiovascular diseases and their associated risk factors remain the main cause of mortality in western societies.
In order to assess the prevalence of cardiovascular risk factors (CVRFs) in the Caucasian population of Lausanne, Switzerland,
we conducted a population-based study (Colaus Study). A secondary aim of the CoLaus study will be to determine new genetic
determinants associated with CVRFs.
Methods: Single-center, cross-sectional study including a random sample of 6,188 extensively phenotyped Caucasian subjects
(3,251 women and 2,937 men) aged 35 to 75 years living in Lausanne, and genotyped using the 500 K Affymetrix chip technology.
Results: Obesity (body mass index ≥ 30 kg/m2), smoking, hypertension (blood pressure ≥ 140/90 mmHg and/or treatment),
dyslipidemia (high LDL-cholesterol and/or low HDL-cholesterol and/or high triglyceride levels) and diabetes (fasting plasma
glucose ≥ 7 mmol/l and/or treatment) were present in 947 (15.7%), 1673 (27.0%), 2268 (36.7%), 2113 (34.2%) and 407 (6.6%)
of the participants, respectively, and the prevalence was higher in men than in women. In both genders, the prevalence of obesity,
hypertension and diabetes increased with age.
Conclusion: The prevalence of major CVRFs is high in the Lausanne population in particular in men. We anticipate that given
its size, the depth of the phenotypic analysis and the availability of dense genome-wide genetic data, the CoLaus Study will be a
unique resource to investigate not only the epidemiology of isolated, or aggregated CVRFs like the metabolic syndrome, but can
also serve as a discovery set, as well as replication set, to identify novel genes associated with these conditions.
Published: 17 March 2008
BMC Cardiovascular Disorders 2008, 8:6 doi:10.1186/1471-2261-8-6
Received: 12 November 2007
Accepted: 17 March 2008
This article is available from: http://www.biomedcentral.com/1471-2261/8/6
© 2008 Firmann et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cardiovascular Disorders 2008, 8:6 http://www.biomedcentral.com/1471-2261/8/6
Page 2 of 11
(page number not for citation purposes)
Background
Cardiovascular diseases (CVD) are the major cause of
early mortality and morbidity in industrialized countries
[1]. The prevalence of classical cardiovascular (CV) risk
factors (CVRFs) such as hypertension, dyslipidemia, obes-
ity and diabetes varies widely between different countries,
and shows some important secular trends
Hypertension, obesity, dyslipidemia and diabetes melli-
tus have an important genetic component [2,3]. These
conditions, however, are genetically complex, and only a
small fraction of these diseases are accounted for by Men-
delian forms. The availability of large case-control
genome-wide association studies has led to the identifica-
tion of susceptibility genes for common conditions, with
even modest effects. Population-based studies have addi-
tional advantages; they make it possible to perform asso-
ciation studies for any continuous phenotypic trait which
has been properly monitored, as well as for categorical
traits using extreme discordant case-control designs, as
long as these conditions are sufficiently prevalent. In addi-
tion, they offer the opportunity to explore the genetic
determinants of aggregated phenotypes such as the meta-
bolic syndrome. Finally, this type of studies provide the
opportunity to perform re-sequencing analysis on
extremes of the distribution, and to identify rare genetic
variants with a strong phenotypic effect [4]. The success of
such studies relies on a large collection, detailed and
standardized phenotypes, strong analytical capabilities,
replication sets and extensive genotyping [5]. To harness
the power of these technologies, we designed the CoLaus
study. The major goals of the CoLaus Core study were to
get a snap picture of the prevalence and severity of CVRFs
in a particular population and to elucidate the molecular
architecture of isolated CVRFs, as well as clusters of CVRFs
like the metabolic syndrome. In this article, we present the
protocol of the study as well as results for the prevalence
of multiple cardiovascular risk factors the Lausanne pop-
ulation.
Methods
Recruitment process and sample size
The Study was approved by the Institutional Ethic's Com-
mittee of the University of Lausanne and recruitment took
place in the city of Lausanne in Switzerland, a town of
117,161 inhabitants, of which 79,420 are of a Swiss
nationality[6].
The complete list of the Lausanne inhabitants aged 35–75
years (n = 56,694 in 2003) was provided by the popula-
tion register of the city and served to sample the partici-
pants to the study. All subjects living in the city of
Lausanne in 2003 for more than 90 days have their name
included in this register. The register had information on
age and gender but no information regarding ethnicity or
country of origin.
Given the allele frequency of most SNPs on the Affymetrix
chip and the genetic effect sizes expected for complex dis-
eases (i.e. OR 1.3 and above), we chose to include ~6000
individuals, so as to have enough power (~80%) to detect
genetic associations for diseases with a prevalence of
~15%.
A simple, non-stratified random selection of 19,830 sub-
jects, corresponding to 35% of the source population, was
drawn using STATA v9.1 software (Stata Corp, College
Station, USA), and a letter inviting the addressee to partic-
ipate in the study was sent to these individuals.
Subjects who volunteered to participate were contacted by
phone within 14 days by one of the staff members to set
up an appointment. Subjects who didn't answer were sent
a second invitation letter. If no answer was obtained, they
were contacted by phone. Subjects were considered as
non-participants if they refused to participate and as non-
responders if contact couldn't be made after two succes-
sive letters and three successive phone calls. Individuals
who didn't live in Lausanne any longer, who were dead or
who didn't meet the age criteria were considered as non-
eligible. Recruitment began in June 2003 and ended in
May 2006.
The sampling procedure is summarized in Figure 1. Of the
initial 19,830 subjects sampled, 54 subjects were consid-
ered as non-eligible before contact and 15,109 (76%)
responses were obtained. A total of 4667 subjects who did
not respond were considered as non-responders. Among
responders, 6,189 (41%) subjects refused to participate in
the study and 799 (5%) were considered as non-eligible.
Among the latter, 53% moved to a different city, 32%
were out of the age range and 11% were reported to be
deceased. The sample of 8,121 subjects who agreed to par-
ticipate represented 41% of the initially sampled popula-
tion, 54% of all responders and 57% of all eligible
responders.
Inclusion criteria
The following inclusion criteria were applied: a) written
informed consent; b) age 35–75 years and c) Caucasian
origin. Caucasian origin was defined as having both par-
ents and grandparents born in a restricted list of countries
(available from the authors). No other exclusion criteria
were applied. Since ethnicity could only be established
during the clinic visit, some participants were assessed but
were not included in the CoLaus study. Their data will be
described elsewhere.
Assessment process
Participants were asked to attend the outpatient clinic at
the Centre Hospitalier Universitaire Vaudois (CHUV) in
the morning after an overnight fast. They had to take their
medication as usual. Data were collected by trained fieldBMC Cardiovascular Disorders 2008, 8:6 http://www.biomedcentral.com/1471-2261/8/6
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interviewers in a single visit lasting about 60 minutes.
Informed consent was obtained from participants upon
their arrival at the study clinic. The first questionnaire
mailed with the appointment's letter and completed by
the participant prior to the morning visit was then quickly
reviewed and a second questionnaire was applied by
interview prior to clinical measurements and blood col-
lection.
Questionnaire data
The first set of questionnaires recorded information on
demographic data, socio-economic and marital status,
and several lifestyle factors, namely tobacco, alcohol and
caffeine consumption, physical activity and mood. Data
on smoking included the previous and current smoking
status as well as the amount of tobacco smoked (number
of cigarettes, cigarillos, cigars or pipes), age of beginning
and end (for former smokers). Similarly, data on alcohol
consumption included the past and current drinking sta-
tus as well as the number of alcoholic beverage units
(wine, beer and spirits) consumed over the week preced-
ing the interview. Caffeine consumption was assessed by
the number of caffeine-containing beverages consumed
per day. Personal history of overweight and/or obesity
and birth weight were also collected. Finally, the 12-item
General Health Questionnaire (GHQ12) [7] was applied
in order to screen for the presence of non-psychotic psy-
chiatric disorders.
The second questionnaire, administered during a face-to-
face meeting with the recruiter, focused on personal and
family history of disease and CV risk factors. Subjects were
asked which disease(s) they or their family had presented.
When a positive answer was given, further information
regarding age of occurrence and number of family mem-
bers affected was collected. When appropriate, death of
parents was recorded with age and cause of death. Regard-
ing blood pressure (BP) status, subjects indicated if they
had been diagnosed with hypertension and subsequently
if they had been, or were being treated currently for this
condition. BP levels before the beginning of treatment
were sought for and the names of the anti-hypertensive
drugs that had been prescribed were collected. In case the
anti-hypertensive regimen had been modified, the dura-
tion and the reason for changing were also recorded. Per-
sonal medicines, including prescription and self-
prescribed drugs, vitamin and mineral supplements,
homeopathy or natural remedies were collected, together
with their main indications. In women, further data
regarding reproductive and obstetrical history, oral con-
traception and hormonal replacement therapy was col-
lected. Finally, an additional frailty questionnaire (for
subjects aged over 50 years) and the Mini-Mental State
Evaluation (MMSE – for subjects aged over 65 years) were
further administered [8].
Clinical data
Body weight and height were measured with participants
standing without shoes in light indoor clothes. Body
weight was measured in kilograms to the nearest 0.1 kg
using a Seca® scale (Hamburg, Germany), which was cali-
brated regularly. Height was measured to the nearest 5
mm using a Seca® height gauge (Hamburg, Germany).
Body mass index (BMI) was defined as weight/height2.
Obesity was defined as BMI ≥ 30 kg/m2 and overweight as
BMI ≥ 25 kg/m2 and < 30 kg/m2 .
BP and heart rate were measured thrice on the left arm,
with an appropriately sized cuff, after at least 10 minute
rest in the seated position using an Omron® HEM-907
automated oscillometric sphygmomanometer (Matsu-
saka, Japan) [9]. The average of the last two measurements
was used for analyses. Hypertension was defined as a
Flow chart of the CoLaus Study Figure 1
Flow chart of the CoLaus Study.BMC Cardiovascular Disorders 2008, 8:6 http://www.biomedcentral.com/1471-2261/8/6
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systolic BP (SBP) ≥ 140 mm Hg and/or a diastolic BP
(DBP) ≥ 90 mm Hg during the visit and/or presence of
anti-hypertensive drug treatment and was considered as
known if the subject was aware of this condition.
In addition, waist and hip circumferences were measured
as recommended [10] and fat and fat-free mass were
assessed by electrical bioimpedance [11] using the Bodys-
tat® 1500 analyzer (Isle of Man, British Isles). Finally,
baldness and its age of onset were assessed in men using
the Hamilton scale [12].
Sub-studies
In addition, sub-studies designed to assess the psychiatric
characteristics of this population as well as functional CV
measurements, were nested onto this study, and will be
described separately.
Biological data
Venous blood samples (50 ml) were drawn after an over-
night fast, and most clinical chemistry assays were per-
formed by the CHUV Clinical Laboratory on fresh blood
samples whereas Pathway Diagnostics (Los Angeles, CA)
measured adiponectin, leptin and insulin [See additional
file 1]. Additional aliquots were stored at -80°C.
LDL-cholesterol was calculated with the Friedewald for-
mula only if triglycerides <4.6 mmol/l. Low HDL choles-
terol level was defined as <1.0 mmol/L; high HDL
cholesterol as ≥ 1.6 mmol/L; high LDL cholesterol was
defined as ≥ 4.1 mmol/L and high triglyceride level was
defined as ≥ 2.2 mmol/L [13]. In our analysis, dyslipi-
demia was defined as low HDL cholesterol and/or high
triglyceride and/or LDL cholesterol ≥ 4.1 mmol/L or ≥ 2.6
mmol/L in presence of self-reported history of myocardial
infarction, stroke, coronary artery disease or diabetes.
Diabetes was defined as fasting plasma glucose ≥ 7.0
mmol/L and/or presence of oral hypoglycaemic or insulin
treatment. Type 2 diabetes mellitus (T2DM) was defined
in case of diabetes without self-reported Type 1 DM. Dia-
betes was considered as known if the subject was aware of
this condition. Impaired fasting glucose (IFG) was
defined as fasting plasma glucose between 6.1 and 6.9
mmol/L without anti-diabetic treatment [14].
A urine sample was collected for the assessment of creati-
nine and albumin and the albumin-to-creatinine ratio
was calculated. Microalbuminuria was defined as a value
of albumin-to-creatinine ratio above 30 mg/g.
Genotyping
Nuclear DNA was extracted from whole blood for whole
genome scan analysis and genotyping was performed
using the Affimetrix 500 K SNP chip, as recommended by
the manufacturer. Subjects consented for the genetic data
to be used for the study of cardiovascular risk factors, and
associated diseases including mood disorders.
Data management, security and quality control
Data were entered into a secured, internet-based database.
The database was designed to confirm the validity of the
identification codes, establish the completeness of the
information keyed in and to perform basic data checks.
All discrepancies were recorded in the case report form
kept in a locked room. Each modification of the data was
automatically recorded, including the identity of the
investigator who made the modification, the date, the old
and the new value.
Staff members were trained and certified before being
involved actively in the study. Certification included abil-
ity to conduct interviews, to perform phlebotomy and to
process blood samples, to accurately measure anthropo-
metric and BP levels and to enter data into electronic data-
bases. The accurateness of the data was checked by an
external quality control organization (PRN, North Hamp-
shire, United Kingdom).
Finally, the 'Laboratoire Central du CHUV' is ISO 9001
certified and is regularly checked by the "Centre Suisse de
Contrôle de Qualité" (CSCQ – Swiss Centre for Quality
Control).
Power estimates and type 1 error rate
Power calculations were done using the program Quanto
v1.1 (James Gauderman, University of Southern Califor-
nia, USA) [15]. Power for unmatched case-control studies
was estimated using an arbitrary allelic frequency ranging
from 0.1 to 0.5, an additive model, a disease prevalence of
50% and a type 1 error rate of 10-7, which was used as a
correction for multiple testing taking into account
500'000 genetics markers. Curves were drawn for esti-
mated genetic effect sizes (odds ratios) of 1.2 to 1.8. To
estimate power in a continuous trait analysis, SBP was
used as a continuous outcome for independent subjects,
with an additive model and a type 1 error rate of 10-7.
Curves were drawn for various minor allele frequencies
(0.1 to 0.5). To minimize false positive results, the most
significant genetic markers will be replicated in independ-
ent samples.
Statistical analysis
Statistical analyses were performed using Stata 9.1 (Stata
Corp, College Station, USA). Results were expressed as
mean ± standard deviation (SD) or as number of subjects
and (percentage). Data for age group 35–75 years and for
the canton de Vaud were extracted from the MONICA
population surveys and used to assess trends [16]. Age at
sampling was used for comparisons between the initialBMC Cardiovascular Disorders 2008, 8:6 http://www.biomedcentral.com/1471-2261/8/6
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population, the random sample and the CoLaus study
population, whereas age at examination was used to
describe the CoLaus Study group characteristics. Compar-
isons were performed using Student's t-test or chi-square
test for quantitative and categorical variables, respectively.
Statistical significance was assessed for p < 0.05.
Sponsoring
The Study was sponsored in part by GlaxoSmithKline and
all participants were duly informed about this sponsor-
ship and consented for the use of biological samples and
data by GlaxoSmithKline and its subsidiaries.
Results
Recruitment
A total of 8121 individuals volunteered to participate in
the study. Among these subjects, the first 6,738 were
invited to attend the clinic and completed the examina-
tion. 549 participants (8.1%) were not of Caucasian eth-
nicity and were excluded from the CoLaus study and
6,189 participants met the inclusion criteria (including
ethnicity) and were included in the CoLaus study. As the
number of subjects who agreed to participate (8,121) was
higher than the number of subjects initially planned for
the CoLaus study (6,000), 1,383 could not be included
into the study although they were willing to participate.
One subject withdrew after consent due to personal rea-
sons. Overall, the final CoLaus sample (n = 6,188) repre-
sents 43% of the eligible responders, 41% of all the
responders and 31% of the initially sampled population.
The gender and age characteristics of the source popula-
tion, the initial random sample and the final CoLaus sam-
ple are summarized in Table 1. Overall, both the sampled
population and the CoLaus study participants were on
average one year younger than the base population, due to
an under-representation of subjects aged over 65 years
while no differences were found for gender distribution.
Further, after excluding non-eligible subjects, no differ-
ences were found regarding mean age and gender distribu-
tion between the subjects included and the random
sample (not shown). The CoLaus Study participants were
significantly older (51.1 ± 0.1 vs. 50.8 ± 0.1 years, p <
0.005) than the random sample, while no differences
were found for gender distribution (not shown). Age at
examination of the participants was on average 2 years
higher than age at sampling because of the time elapsed
between the two procedures. Distribution of the zip codes
within the city was comparable between the base popula-
tion, the random sample and the CoLaus study partici-
pants (not shown).
Socio-economic characteristics of the CoLaus study 
participants
The CoLaus Study participants' main characteristics are
summarized in Table 2. No gender differences were found
regarding the percentage of foreigners. Overall, women
were more frequently divorced, widowed or single than
men and thus were living more often alone or as a mon-
oparental family (41.7% vs. 23.6%, p < 0.01). Women
were also less frequently on a full-time job, more prone to
receive social help (26.2% vs. 22.2%, p < 0.001) and had
a lower educational level. Among subjects aged less than
40 years old, 48.4% of women had a high school/college/
university degree versus 47.4% of men (p < 0.01).
Clinical characteristics of the CoLaus Study participants
Men had a higher BMI, waist/hip ratio, systolic and DBP
levels, but lower body fat percentage, than women. [Table
3]. Men had higher total cholesterol and triglyceride lev-
els, but lower HDL cholesterol, than women. Fasting
blood glucose levels, homocystein, apolipoprotein B,
insulin, NT-proBNP and uric acid were higher in men
than in women [Tables 3 and 4]. Conversely, women pre-
sented higher LDL cholesterol particle size, adiponectin,
leptin and hsCRP than men.
Table 1: Distribution of participants by age and sex in the source population, the initial random sample and the CoLaus Study 
participants.
Source population (n = 56,694) Random sample (n = 19,830) CoLaus Study (n = 6,188)
Women (%) 30,141 (53.4) 10,601 (53.5) 3,251 (52.5)
P value 0.79 0.08
Age (years) 52.0 ± 11.6 50.8 ± 11.5 51.1 ± 10.9
P value <0.001 <0.001
Age group
35–44 18.877 (33.4) 7,265 (36.6) 2,051 (33.1)
45–54 14,614 (25.9) 5,202 (26.2) 1,682 (27.2)
55–64 12.484 (22.1) 4,417 (22.3) 1,657 (26.8)
65–75 10,524 (18.6) 2,946 (14.9) 798 (12.9)
P value <0.001 <0.001
Results are expressed as number of subjects and (percentage) or as mean ± SD. Statistical analysis by Student's t-test or chi-square test compared 
to the source populationBMC Cardiovascular Disorders 2008, 8:6 http://www.biomedcentral.com/1471-2261/8/6
Page 6 of 11
(page number not for citation purposes)
CVRFs within the CoLaus study
More than one third of the overall sample was overweight,
and slightly less than one-sixth was obese; overweight and
obesity were also more prevalent in men [Table 5] and
increased with age. In men aged 35–44 years, the preva-
lence of overweight and obesity were 40.7% and 11.4%,
respectively, whereas in men aged 65–75 the correspond-
ing figures were 50.8% and 22.7% (p < 0.001). The corre-
sponding figures for women were 21.9% and 9.6%, and
35.8% and 17.5% (p < 0.001), respectively.
Smoking was reporter by 27% of the participants; the
prevalence of current smoking was higher in men and
tended to decrease with age, from 35.3% among 35–44
year olds to 20.7% among 65–75 year olds in men (p <
0.001), the corresponding figures being 28.1% and 14.7%
in women (p < 0.001). Interestingly, in the 45–54 age
class, prevalence of smoking was higher in women than in
men (30.7% vs. 28.8% (p < 0.001)).
The prevalence of hypertension was 36.7% overall, was
higher in men and increased with age: 18.3% and 75.1%
in men aged 35–44 and 65–75, respectively (p < 0.001);
the corresponding numbers in women were 9.9% and
59.1% (p < 0.001). Among hypertensive subjects, 50.1%
were currently taking anti-hypertensive medication. Treat-
Table 2: Socio-economic characteristics of the participants in the CoLaus Study.
Overall (n = 6,188) Women (n = 3,251) Men (n = 2,937) P value
Born in Switzerland (%) 3,997 (64.6) 2,129 (65.5) 1,868 (63.6) 0.12
Marital status (%)
Single 1,022 (16.5) 569 (17.5) 453 (15.4)
Married 3,635 (58.8) 1,673 (51.5) 1,962 (66.9) <0.001
Divorced 1,242 (20.1) 761 (23.4) 481 (16.4)
Widowed 287 (4.6) 248 (7.6) 39 (1.3)
Education (%)
Basic 1,287 (20.8) 777 (23.9) 510 (17.4)
Apprenticeship 2,286 (37.0) 1,170 (36.0) 1,116 (38.0) <0.001
High school/college 1,470 (23.9) 804 (24.8) 666 (22.7)
University 1,140 (18.4) 497 (15.3) 643 (21.9)
Work status (%)
Full time 3,790 (61.2) 1,694 (52.1) 2,096 (71.4) <0.001
Other 2,398 (38.8) 1,557 (47.9) 841 (28.6)
Results are expressed as number of subjects and (percentage). Comparison between gender was performed using chi-square test.
Table 3: Clinical characteristics of the participants in the CoLaus study, by gender.
Overall (n = 6,188) Women (n = 3,251) Men (n = 2,937) P value
Age (years) 53.1 ± 10.8 53.5 ± 10.7 52.6 ± 10.8 <0.001
Waist/hip ratio 0.88 ± 0.08 0.83 ± 0.07 0.93 ± 0.06 <0.001
BMI (kg/m2) 25.8 ± 4.6 25.1 ± 4.9 26.6 ± 4.0 <0.001
Body fat (%) 29.3 ± 9.0 34.4 ± 8.2 23.8 ± 6.1 <0.001
Systolic BP (mm Hg) 128 ± 18 125 ± 18 132 ± 17 <0.001
Diastolic BP (mm Hg) 79 ± 11 78 ± 11 81 ± 11 <0.001
Total cholesterol (mmol/L) 5.59 ± 1.04 5.61 ± 1.03 5.56 ± 1.04 <0.05
HDL cholesterol (mmol/L) 1.63 ± 0.44 1.81 ± 0.43 1.44 ± 0.36 <0.001
Triglycerides (mmol/L) 1.40 ± 1.18 1.16 ± 0.66 1.66 ± 1.52 <0.001
LDL cholesterol particle size (nm) 272 ± 4 273 ± 4 271 ± 5 <0.001
Apolipoprotein B (mg/dL) 1.74 ± 1.34 1.69 ± 1.29 1.80 ± 1.38 <0.005
Glucose (mmol/L) 5.55 ± 1.15 5.34 ± 1.02 5.78 ± 1.23 <0.001
Insulin (μU/mL) 8.44 ± 6.3 7.97 ± 5.47 9.62 ± 6.78 <0.001
Adiponectin (μg/mL) 9.94 ± 8.12 12.32 ± 9.33 7.32 ± 5.43 <0.001
Leptin (ng/mL) 13.1 ± 10.7 16.9 ± 11.7 8.65 ± 7.3 <0.001
Homocystein (μmol/L) 10.4 ± 4.4 9.4 ± 3.2 11.4 ± 5.2 <0.001
hsCRP (mg/L) 2.49 ± 3.48 2.65 ± 3.71 2.30 ± 3.21 <0.001
Pro-BNP (ng/L) 682 ± 531 679 ± 519 686 ± 545 0.60
Results are expressed as mean ± SD. BMI: body mass index; HDL: high density lipoprotein, hsCRP: high sensitivity C-reactive protein, BNP: brain 
natriuretic peptide. Statistical analysis between gender by Student's t-test or chi-square test.BMC Cardiovascular Disorders 2008, 8:6 http://www.biomedcentral.com/1471-2261/8/6
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ment for hypertension was more frequent in female sub-
jects and increased with age (from 32.2% to 59.4%). Of
the treated hypertensive subjects more than half (52.0%)
had BP levels ≥ 140/90 mmHg.
High LDL cholesterol, high triglyceride and low HDL cho-
lesterol levels were seen in 20.8%, 12.5% and 2.8% of the
subjects, respectively and these conditions were also more
prevalent in men. The prevalence of high HDL cholesterol
was 53.4% and higher in women than men (71.6% vs.
33.2%). Overall, one third of the sample had dyslipi-
demia, the prevalence of which was higher in men
(42.7%) than in women (26.6%).
Use of statin therapy in subjects with high LDL cholesterol
was 5.6%. Prevalence of statin therapy was 69% in sub-
jects after myocardial infarction, 33% in subjects after
stroke and 70% in subjects after coronary artery bypass
graft. Target level of LDL-cholesterol for secondary pre-
vention, as recommended (< 2.6 mmol/l), was achieved
in 28%, 38%, 28% and 33% of the subjects with diabetes,
Table 4: Clinical characteristics of the participants of the CoLaus study, by gender.
Overall (n = 6,188) Women (n = 3,251) Men (n = 2,937) P value
ASAT (U/L) 29.96 ± 14.04 26.22 ± 9.88 34.10 ± 16.57 <0.001
ALAT (U/L) 27.84 ± 19.50 21.98 ± 14.47 34.32 ± 22.13 <0.001
Alkaline phosphatase (U/L) 63.47 ± 20.72 62.66 ± 20.99 64.38 ± 20.38 <0.001
Gamma-GT (U/L) 33.20 ± 59.04 22.95 ± 25.78 44.57 ± 79.80 <0.001
Calcium (mmol/L) 2.29 ± 0.09 2.28 ± 0.10 2.29 ± 0.09 <0.001
Albumin (g/L) 44.20 ± 2.53 43.73 ± 2.48 44.71 ± 2.48 <0.001
Total protein (g/L) 74.41 ± 4.39 73.93 ± 4.42 74.95 ± 4.30 <0.001
Uric acid (μmol/L) 313.49 ± 84.47 270.56 ± 67.23 361.08 ± 75.69 <0.001
CDT (% of total transferrin) 0.95 ± 0.81 0.80 ± 0.48 1.12 ± 1.02 <0.001
Results are expressed as mean ± SD. ASAT: Aspartate amino-transferase. ALAT: Alanine amino-transferase. Gamma-GT: Gamma-glutaryl-
transferase. CDT: Carbohydrate deficient transferrin. Statistical analysis between genders by Student's t-test or chi-square test.
Table 5: Prevalence of selected cardiovascular risk factors in the participants of the CoLaus study.
Overall (n = 6,188) Women (n = 3,251) Men (n = 2,937) P value
BMI status (%)
Overweight 2265 (36.6) 922 (28.4) 1343 (45.7) <0.001
Obesity 974 (15.7) 472 (14.5) 502 (17.1)
Smoking status (%)
Current 1673 (27.0) 813 (25.0) 860 (29.3)
Former 2034 (32.9) 904 (27.8) 1130 (38.5) <0.001
Never 2479 (40.1) 1534 (47.2) 945 (32.2)
Blood pressure status (%)
Hypertension 2268 (36.7) 1004 (30.9) 1264 (43.0) <0.001
Treated hypertension 1131 (50.1) 537 (53.8) 594 (47.1) <0.005
Treated to goal 542 (48.0) 271 (50.6) 271 (45.6) NS
Lipid status (%)
High LDL cholesterol 1263 (20.8) 631 (19.5) 632 (22.2) <0.001
High triglycerides 773 (12.5) 216 (6.7) 557 (19.0) <0.001
Low HDL cholesterol 170 (2.8) 35 (1.1) 135 (4.6) <0.001
High HDL cholesterol 3296 (53.4) 2324 (71.6) 972 (33.2) <0.001
Dyslipidemia 2113 (34.2) 862 (26.6) 1251 (42.7) <0.001
Treated dyslipidemia 286 (13.5) 95 (11.0) 191 (15.3) <0.001
Glycaemic status (%)
Diabetes 407 (6.6) 130 (4.0) 277 (9.5) <0.001
Known Diabetes 270 (66.3) 89 (68.5) 181 (65.3) <0.005
Treated Diabetes 260 (96.3) 85 (95.5) 175 (96.7) <0.01
Microalbuminuria (%) 380 (6.3) 173 (5.4) 207 (7.3)
Overweight: BMI ≥ 25 kg/m2. Obesity: BMI ≥ 30 kg/m2. Hypertension: Blood pressure ≥ 140/90 mmHg and/or presence of anti-hypertensive 
drug treatment. Low HDL cholesterol: <1 mmol/L; high HDL cholesterol: ≥ 1.6 mmol/L; high LDL cholesterol: ≥ 4.1 mmol/L and high 
triglyceride: ≥ 2.2 mmol/L. Dyslipidemia: low HDL cholesterol and/or high triglyceride and/or LDL cholesterol ≥ 4.1 mmol/L or ≥ 2.6 mmol/L in 
presence of self-reported myocardial infarction, stroke, coronary artery disease or diabetes. Diabetes: fasting plasma glucose ≥ 7 mmol/L and/or 
presence of oral hypoglycaemic or insulin treatment. Microalbuminuria :albumin-to-creatinine ratio > 30 mg/gBMC Cardiovascular Disorders 2008, 8:6 http://www.biomedcentral.com/1471-2261/8/6
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myocardial infarction, stroke and coronary artery bypass
graft, respectively.
The overall prevalence of diabetes was 6.6%, and was
higher in men. Nine subjects (2.2%) reported to have
T1DM. The prevalence of diabetes increased with age,
from 2.5% to 17.2% in men aged 35–44 and 65–75,
respectively; the corresponding numbers were 1.2% and
9.0% in women with a peak prevalence of 17.2% in men
aged > 65. Roughly a third were newly diagnosed diabetics
(31.5% for women and 34.7% for men, respectively). The
prevalence of IFG in the CoLaus population was 9.8% and
was higher in men than in women (14.3% vs. 5.6%).
Treatment for diabetes was present in 73.9% of diabetic
subjects but nearly all known diabetics were treated
(96.3%). Of the treated diabetic subjects 63.9% had a fast-
ing blood glucose ≥ 7 mmol/L, at the time of their visit.
Finally, 0.7% of women and 2.6% of men reported a per-
sonal history of myocardial infarction (p < 0.001); con-
versely, no gender differences were found regarding
personal history of stroke: 1.0% of women vs. 1.3% of
men, p = 0.16.
Power estimates
The power of the CoLaus study for an unmatched case-
control design to study genotype/phenotype associations
depends on the number of cases/controls and estimated
effect size [Figure 2]. For hypertension with 2268 cases,
the estimated power is 0.9 for a 1.4 effect size and 0.5 for
a 1.3 effect size. Cases for main CVRFs in the CoLaus study
are: dyslipidemia: 2021, obesity: 974, smoking (> 25 cig-
arettes/day): 746, Type 2 diabetes: 398, coronary heart
disease: 262, low HDL: 170. For continuous trait analysis,
the example of SBP was taken [Figure 3]. For allelic fre-
quencies of 0.2 to 0.4, the study has an estimated power
of >0.8 to detect BP variations of 2.0 – 2.3 mm Hg.
Discussion
Described in this report are the rationale, objectives,
methods and first results from the CoLaus study, a single-
center population-based sample including 6188 exten-
sively phenotyped Caucasian subjects aged 35–75. Our
results indicate that the prevalence of major CVRFs is
high, in particular in men. In addition, this collection rep-
resents a powerful tool to identify new molecular determi-
nants of CVRFs and associated diseases [17].
The participation rate of 41% in the CoLaus study is com-
parable to the MONICA surveys conducted in Switzerland
and in France [18]. The lower response rate among elderly
subjects is in agreement with previous data [19] and
might be related to a lower interest for the study. How-
ever, the distribution of age groups 35–54 and 55–75 in
the CoLaus study was comparable to the source popula-
tion [Table 1]. Also, there was no gender or zip code dis-
tribution difference between the source population, the
random sample and the CoLaus participants. Although
the optimal sampling frame would have consisted of a list
of all Caucasians living in the city, information on ethnic-
ity was not available to the investigators before examina-
tion and it is not possible to assess whether ethnicity had
an effect on the participation rate.
The prevalence of main CVRFs was high in the CoLaus
participants. Roughly over half of the participants pre-
sented with overweight and obesity, over a third had high
BP or dyslipidemia while one in 15 participants had dia-
betes.
In agreement with the literature [20], men had a higher
prevalence of obesity and overweight than women. Fur-
ther, comparison with data from the MONICA study sug-
gests that the prevalence of obesity is increasing, which
confirms what has been found in the nearby city of
Geneva [21]. Compared to data from the National Health
Examination Survey (NHANES) in the United States
(1999–2004), the prevalence of obesity remains lower in
Lausanne[22]. The higher prevalence of overweight in
men might also account for their higher prevalence of dia-
betes and hypertension. In clinical practice, the diagnosis
of hypertension relies on several consecutive BP measure-
ments but as in most epidemiological studies, BP meas-
urements were conducted during a single visit [23].
Terminal digit preference in BP readings may induce a
bias, a consistency check was conducted showing no sig-
nificant deviation of terminal digit frequency from the
10% value for all BP measurements (not shown). The
prevalence of hypertension was higher in men than in
women and increased with age. Interestingly, the gender-
specific prevalence rates found in the CoLaus study were
similar to those previously reported for the same age
group in Italy [24] and in nearby Geneva [21]. We also
observed that over half of the treated hypertensive sub-
jects had a BP ≥ 140/90 mmHg at the time of their exam-
ination, indicating the continuous need to improve
treatment compliance. The prevalence of diabetes was
6.6% and was significantly higher in men and in particu-
lar after the age of 55 years. These numbers are similar to
other Swiss estimates [25] and to the KORA Augsburg
study in the southern part of Germany [26]. About a quar-
ter of the CoLaus participants were smokers, a figure quite
similar to the data reported for the Geneva population in
2003 [21] and somewhat lower than those observed in
the USA[27]. The prevalence of smoking was higher in
men than in women, although this difference tended to
decrease among younger age groups, as previously
reported [28]. Indeed, in the age group 45–54, the preva-
lence of smoking was higher in women than in men, sug-BMC Cardiovascular Disorders 2008, 8:6 http://www.biomedcentral.com/1471-2261/8/6
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gesting that the "gender gap" regarding smoking no longer
exists for middle-aged subjects.
The high prevalence of CVRFs in this study population
underscores the necessity to increase disease awareness, to
improve screening in high risk subjects and to promote
prevention both at the public health and individual level.
Recently, an increasing number of reports have demon-
strated the power of whole genome association studies
approach in complex diseases such as diabetes [29], obes-
ity [30] and cardiovascular disease [31]. The size of the
CoLaus study, the population-based design and the in-
depth phenotypisation were chosen in order to harness
the power of this technology using dichotomous and con-
tinuous trait analyses. In particular, this ensures an identi-
cal phenotypisation in cases and controls, which has been
a limitation in some of the recently published reports [32]
and allows to study complex traits such as the metabolic
syndrome. Combined analysis of our results with other
datasets has already allowed to identify new genetic deter-
minants associated with circulating LDL-plasma levels
[17] (similar results were published concomitantly by
other groups [33,34]) and determinants associated with
height [35]. Additional analysis are currently ongoing.
Perspectives
A more comprehensive characterization of the Colaus par-
ticipants is currently ongoing. First all participants aged 35
to 65 were solicited to undergo a psychiatric investigation
based on a semi-structured diagnostic interview. In addi-
tion, 500 subjects were assessed for CV functional measure-
ments. Indeed several previous studies have revealed
associations between mood disorders and, in particular
depression, and CVRFs and CV diseases (reviewed in [36]).
The availability of a simultaneous CV and psychiatric phe-
notype will allow us to further explore the epidemiologic
and potentially a genetic basis for this association. Finally,
500 randomly selected non-diabetic individuals underwent
a 2 hour glucose tolerance test. The results from these inves-
tigations will be reported separately.
A longitudinal follow-up of all participants in the CoLaus
study is planned and shall provide essential data for
trends over time of major CVRFs and on incident cases of
CV diseases. In the current cross-sectional study, partici-
pants were asked whether they consented to be contacted
for follow-up, with > 90% favorable responses.
Conclusion
In summary, these initial results from the CoLaus study
show that the prevalence of main CVRFs is high in the
Power estimates for the CoLaus study Figure 2
Power estimates for the CoLaus study. Power for 
various sample sizes in unmatched case-control stud-
ies. Arbitrary allelic frequency of 0.3, a disease prevalence of 
50% and a type 1 error rate of 10-7taking into account 
500'000 genetics markers. Curves are for estimated genetic 
effects (odds ratios) of 1.2 to 1.8. The numbers of cases for 
main CVRFs in the CoLaus study are: Hypertension: 2268. 
Dyslipidemia: 2021. Obesity: 963. Smoking (> 25 cigarettes/
day): 746. Type 2 diabetes: 398. Coronary heart disease: 262. 
Low HDL: 170.
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Caucasian population of Lausanne, and in particular in
men. This emphasizes the need for continued epidemio-
logical monitoring and for strengthening interventions to
reduce the prevalence and severity of CVRFs in this popu-
lation. This population-based study with over 6000 exten-
sively characterized and genotyped participants
constitutes a unique resource to identify new or replicate
suspected or known molecular determinants of CVRFs
and associated diseases.
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